The Equation Series
Menu

Healthcare · Profile from Healthcare Research Companion

Envision Healthcare Corporation

The Nashville-based physician-staffing company that ran emergency departments, anesthesia, hospitalist, radiology and neonatology services for hundreds of US hospitals. It went from a Dallas emergency-physician group (EmCare, 1972) through four owners (Laidlaw, Onex, Clayton Dubilier & Rice, the public markets), a merger with surgery-center operator AmSurg (2016) and a ~$9.9bn KKR buyout (2018) to Chapter 11 in May 2023. Its story is the clearest case in US healthcare of a business whose margins depended on patients being unable to choose their doctor, and of what happens to a leveraged company when the law closes that gap.

At a glance

Founded
1972, Dallas, Texas, as EmCare (emergency-physician contract management), founded by Dr. Leonard Riggs and colleagues (reported)
Founders
Leonard M. Riggs Jr., MD, emergency physician, and partners (verify full founding group)
Headquarters
Nashville, Tennessee (after the 2016 AmSurg merger); earlier Greenwood Village, Colorado (EMSC/Envision) and Dallas (EmCare)
Ownership / structure
Private. Owned by its former lenders since emerging from Chapter 11 in November 2023 (reported). Earlier: Laidlaw (1997–2005), Onex (2005–2011, public as EMSC from December 2005), CD&R (2011–2013, then public as Envision Healthcare Holdings, NYSE: EVHC, 2013–2016), Envision Healthcare Corp (NYSE: EVHC, 2016–2018), KKR (2018–2023)
Leadership (2026)
Jason Owen, President and CEO (effective 15 April 2024, after CFO Henry Howe served as interim CEO). Former CEOs: William Sanger (EMSC/Envision), Christopher Holden (AmSurg, then Envision December 2016–February 2020), Jim Rechtin (February 2020–December 2023, then Humana CEO)
Segment
Provider: hospital-based physician services (emergency medicine, hospital medicine, anesthesiology, radiology, neonatology, surgical services); formerly ambulance (AMR, sold 2017–18) and ambulatory surgery (AmSurg, separated 2023)
Payer and patient
Commercial insurers, Medicare, Medicaid and uninsured patients billed by the physician group; hospitals pay subsidies or management fees where professional revenue does not cover cost. Patients are mostly emergency and inpatient patients who did not choose the clinician
Scale
Peak ~25,000+ clinicians and ~$7.8bn revenue (2017, with AmSurg, continuing operations excluding AMR; 10-K); ~17,000+ clinicians after emergence (2023–24, reported)
Capital / price
EMSC IPO December 2005; CD&R buyout ~$3.2bn including debt (2011); Envision IPO ~$1bn (August 2013, reported); AmSurg merger ~$15bn combined enterprise value (2016); KKR take-private ~$9.9bn including debt (2018); Chapter 11 with ~$7.7bn of funded debt (May 2023); AmSurg sold to Ascension for ~$3.9bn (announced June 2025, completed 2026, reported)
Signature moves (incl. failures)
Laidlaw spin-out as EMSC (2005); CD&R buyout (2011); Envision IPO (2013); AmSurg merger and AMR sale (2016–18); surprise-billing exposure and UnitedHealthcare fight (2017–21); KKR LBO (2018); dark-money campaign and the No Surprises Act (2019–22); Chapter 11 and AmSurg split (2023)

8 strategic moves analysed

Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.

  1. 2005

    EMSC Spinout from Laidlaw

    Divestiture (carve-out by a financial sponsor) / IPO

  2. 2011

    CDR Buyout of EMSC

    Acquisition (leveraged take-private)

  3. 2013

    Envision IPO

    IPO (sponsor-backed re-listing)

  4. 2016

    AmSurg Merger

    Merger (all-stock "merger of equals") / divestiture

  5. 2017

    Surprise Billing Exposure and UHC Fight

    Pricing / network strategy and payer dispute (exposed by research and press)

  6. 2018

    KKR Take Private

    Acquisition (leveraged buyout)

  7. 2019

    Dark Money Campaign and No Surprises Act

    Lobbying and advocacy campaign / regulatory change

  8. 2023

    Chapter 11 and AmSurg Separation

    Bankruptcy / restructuring / divestiture